Abstract Number: 451 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data 3 In Patients With Rheumatoid Arthritis Receiving Tocilizumab
Background/Purpose: Interleukin-6 (IL-6) has been demonstrated to play a pathological role in rheumatoid arthritis (RA). IL-6 strongly induces production of C-reactive protein (CRP) and fibrinogen…Abstract Number: 2683 • 2013 ACR/ARHP Annual Meeting
Application Of a Multi-Biomarker Disease Activity (Vectra® DA) Score For Assessing Rheumatoid Arthritis Patients With Fibromyalgia Or Low C-Reactive Protein
Background/Purpose: Clinical assessment of rheumatoid arthritis (RA) may be challenging if patients have fibromyalgia (FM) or if C-reactive protein (CRP) is low (£1 mg/dL). A…Abstract Number: 2279 • 2013 ACR/ARHP Annual Meeting
Assessment Of Global Disease Activity In Rheumatoid Arthritis By Patients and Physicians: Cultural Differences Among Countries In The Meteor Database
Background/Purpose: Dissonant perceptions of disease activity between rheumatoid arthritis (RA) patients and their rheumatologists may influence treatment decisions. The discordance between patient's and physician's global…Abstract Number: 1863 • 2013 ACR/ARHP Annual Meeting
SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity
Background/Purpose: Type I interferon (IFN-I) has been implicated in SLE pathogenesis, and cross-sectional studies have shown that IFN-I pathway activation is associated with multiple disease…Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis
Background/Purpose: Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…Abstract Number: 1026 • 2013 ACR/ARHP Annual Meeting
Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments
Background/Purpose: Current guidelines recommend treatment for rheumatoid arthritis (RA) be informed by a measure of disease activity such as the Disease Activity Score-28 (DAS28-CRP), which…Abstract Number: 422 • 2013 ACR/ARHP Annual Meeting
Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry
Background/Purpose :Disease activity is related to risk of cardiovascular (CV) disease in rheumatoid arthritis (RA) patients1,2. Left ventricular (LV) geometry strongly predicts CV mortality and…Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting
Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice
Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist, though an evidence base for their use in monitoring…Abstract Number: 2280 • 2013 ACR/ARHP Annual Meeting
Stiffness From The Perspective Of People Living With Rheumatoid Arthritis
Background/Purpose: Stiffness was included in the 1961 and 1987 Rheumatoid Arthritis (RA) classification criteria and continues to be commonly queried in clinical care. Its relative…Abstract Number: 1788 • 2013 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Test (Vectra® DA) Estimates Risk Of Radiographic Progression For Patients With Rheumatoid Arthritis From The Leiden Early Arthritis Clinic
Background/Purpose: The multi-biomarker disease activity (MBDA) blood test assesses disease activity in patients with rheumatoid arthritis (RA) using a validated algorithm to provide a score…Abstract Number: 1357 • 2013 ACR/ARHP Annual Meeting
Coping Style Is An Independent Predictor For Disease Activity At Three Months In Early Arthritis Patients Initiating Therapy With Disease Modifying Anti-Rheumatic Drugs
Background/Purpose: To explore the effect of psychosocial factors on the Disease Activity Score (DAS) and its components in early arthritis patients three months after initiating…Abstract Number: 1029 • 2013 ACR/ARHP Annual Meeting
Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea
Background/Purpose: Quality of life (QOL) is a well-established outcome for rheumatoid arthritis (RA) trials. To perform trials with QOL as an outcome involving many countries,…Abstract Number: 380 • 2013 ACR/ARHP Annual Meeting
Active Rheumatoid Arthritis Is An Independent Risk Factor Of Chronic Kidney Disease
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects not only joints but also many organs. RA causes vascular damages to contribute to…Abstract Number: 2569 • 2013 ACR/ARHP Annual Meeting
Serum S100A4 Levels Correlate With Skin Fibrosis and Lung Involvement In Systemic Sclerosis
Background/Purpose: Our previous study demonstrated that S100A4 is overexpressed in scleroderma (SSc) skin, fibroblasts and preclinical models of SSc in a TGF-β dependent manner. Furthermore,…Abstract Number: 2251 • 2013 ACR/ARHP Annual Meeting
Variability in the Classification of Remission Among Disease Activity Indices and Their Correlation: An Analysis From a Prospective, Observational Registry
Background/Purpose: In recent years, disease remission in rheumatoid arthritis (RA) has been assessed using various disease activity indices such as the DAS28-CRP, SDAI, CDAI, ACR/EULAR-recommended…
- « Previous Page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- …
- 102
- Next Page »